Evaluation of autonomic dysfunction in hereditary transthyretin amyloidosis.

F Martínez-Valle, C Casasnovas-Pons, M Romero-Acebal, L Galán-Dávila

Journal: Neurologia 2025;40(9):915-923

PMID: 41198384

Abstract

BACKGROUND

Autonomic dysfunction is a common manifestation of hereditary transthyretin (ATTRv) amyloidosis that frequently appears early and has a major impact on disease severity, survival, and quality of life. Early detection of autonomic symptoms is paramount to avoid delayed diagnosis or misdiagnosis of ATTRv amyloidosis and thereby achieve timely interventions with novel therapies. We thus require a better understanding and recognition of the warning signs of autonomic nervous system involvement in patients with ATTRv amyloidosis.

DEVELOPMENT

According to the literature and the expertise of key opinion leaders on ATTRv amyloidosis, early signs and symptoms of autonomic dysfunction often include orthostatic hypotension, gastrointestinal disturbances, and cardiac and sudomotor sympathetic denervation. Assessment methods for a rapid and accurate diagnostic thus comprise blood pressure monitoring, nutritional status evaluation, cardiac imaging techniques, and pathological and neurophysiological tests assessing small fiber function. The COMPASS-31 and Norfolk QOL-DN tests allow assessment of the severity of autonomic dysfunction and its impact on quality of life, respectively.

CONCLUSION

The screening strategy for autonomic dysfunction should involve diverse neurological and non-neurological tests to encompass the wide variety of potential manifestations of autonomic dysfunction in ATTRv amyloidosis. Further studies addressing the correlations among different tests and their prognostic value in different TTR variants are required to establish a single standardized method or the minimum set of tests needed to assess autonomic dysfunction in ATTRv amyloidosis patients.

Copyright © 2024 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. All rights reserved.

Address: Autoimmune Diseases Unit, Internal Medicine Department, Vall d'Hebron Hospital, Vall d'Hebron Institut de Recerca, Spain. Electronic address: [email protected].; Neuromuscular Unit, Neurology Department, Bellvitge University Hospital-IDIBELL, Multidisciplinary Unit of Familiar Amyloidosis, Neurometabolic Diseases Group, Bellvitge Biomedical Research Institute (IDIBELL), Biomedical Research Network Center in Rare Diseases (CIBERER), Spain.; Servicio de Neurología, Hospital Universitario Virgen de la Victoria, Málaga, Spain.; Neurology Department, Hospital Clínico San Carlos, IdiSSC, Spain.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.